CereMark Pharma to Test F-18 Flornaptitril in Phase III Trial for Neurodegenerative Diseases

Later this year, a phase III clinical trial will be conducted by radiopharmaceutical company CereMark Pharma, which specialises in neurodegenerative illnesses, to study the new PET imaging agent F-18 flornaptitril.The goal of F-18 flornaptitril is to specifically target two pathogenic proteins involved in the progression of chronic traumatic encephalopathy and Alzheimer's disease. The study will concentrate on warriors and sportsmen who exhibit the early signs of moderate cognitive impairment. To assist its planned clinical investigations, CereMark has announced a relationship with Hall of Fame Health.

According to CereMark, comprehension of the density and spatial distribution of tau protein aggregation and beta-amyloid plaques in different brain areas is essential for managing patients effectively and comprehending the course of neurodegeneration.

The decision to designate traumatic brain injuries as a chronic illness was made recently.The company told AuntMinnie.com that unbundling payments for PET radiotracers would spur development and innovation inside businesses like CereMark, and that the recent decision to designate traumatic brain injuries as a chronic disease is a gain for patients.